

**S4 Table.** Adverse effects ( $\geq$  grade 2) associated with initial EGFR-TKI therapy

	<b>Gefitinib (n=45)</b>	<b>Erlotinib (n=14)</b>
Adverse effect	21 (46.7)	9 (64.3)
Skin rash	12 (26.7)	5 (35.7)
Mucositis	2 (4.4)	3 (21.4)
Gastrointestinal symptoms	4 (8.9)	0
Paronychia	1 (2.2)	1 (7.1)
Abnormal liver function test <sup>a)</sup>	2 (4.4)	0
No reported adverse effects	24 (53.3)	5 (35.7)

Values are presented as number (%). EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor. <sup>a)</sup>Two patients with LFT elevation held the EGFR-TKI therapy for 2 weeks and restarted after LFT was in the normal range.